Every day, more clinicians and patients discover the simplicity and convenience of using Somatuline^® Depot (lanreotide) Injection to treat acromegaly. At Tercica, our commitment to improving the lives of patients who use our products doesn't stop at the point of prescription. We are committed to further exploration and development of Somatuline^® Depot through a phase IV observational study and clinical trials.

SODA Observational Study
We invite all physicians who prescribe Somatuline^® Depot to play an important role in this process by becoming clinical investigators in the Somatuline^® Depot for Acromegaly (SODA) Observational Study.

The SODA Observational Study, which will begin in 2008, is designed to collect post-approval data on the safety and efficacy of Somatuline^® Depot in acromegaly when administered by a health care professional, the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

All healthcare professionals who participate in the SODA Observational Study receive one-on-one, on-site training in using our simple, Web-based data collection system. Data is collected through a secure Web site, and is kept confidential in full compliance with federal regulations. Among the types of data included in the analysis are demographics, previous medical histories, physical growth parameters and dosing history. As data is collected on patients enrolled at centers throughout the United States, it is then analyzed for use in scientific publications, presentations and at annual meetings of clinical investigators and study coordinators.

To inquire about participating in the SODA Observational Study, call 1.866.TERCICA

Tercica is also conducting or planning additional clinical studies at specific study sites in the United States and Canada. Examples of these studies include:

Study MS315: The Assessment of the Self-Administration and/or Partner Administration of Somatuline^® Depot (lanreotide) Injection in Subjects with Acromegaly. The objective of this study is to evaluate proper technique and effectiveness of Somatuline^® Depot (lanreotide) Injection at home. This Phase III, multicenter, nonrandomized, open-label, single-group assignment study is designed to assess approximately 60 subjects, and enrollment is now complete.